Navigation Links
IVI announces the prequalification of innovative cholera vaccine by the World Health Organization
Date:11/11/2011

SEOUL, KOREA -- Shanchol, a new oral cholera vaccine developed through the International Vaccine Institute (IVI), an international organization established by the United Nations and based in Seoul, recently received prequalification from the World Health Organization (WHO). Developed for use in developing countries to protect against life-threatening cholera, Shanchol is ready to use in a single-dose vial and is administered orally, which facilitates its implementation in large-scale immunization programs. Shanchol is produced by Shantha Biotechnics part of the Sanofi group - in India where the vaccine has been licensed and sold since 2009.

"I am immensely pleased by the news that Shanchol, a vaccine enabled by IVI, received WHO prequalification," said Dr. Christian Loucq, IVI's new Director General. "This stamp of approval shows that public-private partnerships - such as those among IVI, Vabiotech, Shantha and Sanofi are essential for successful vaccine development, particularly in developing vaccines against neglected diseases of the poor like cholera."

Certification by WHO of Shanchol represents a major milestone as it indicates that the vaccine meets WHO standards of quality, safety and efficacy, and allows the vaccine to be procured by UN agencies and other international organizations for use in countries around the world. It also accelerates international use of the vaccine since WHO prequalification eliminates the need for country-level market authorization in some countries, which can take years to obtain.

WHO prequalification of Shanchol is the latest achievement in IVI's mission to develop and introduce innovative, safe, and effective vaccines to protect vulnerable populations in poor countries against deadly diseases including cholera. With financial support from the Bill & Melinda Gates Foundation and the governments of Korea and Sweden, and technical support from scientists in Sweden, as well as at Vietnam's National Institute of Hygiene and Epidemiology and production experts at Shantha, IVI enabled technology transfer from Vabiotech, a vaccine manufacturer in Vietnam, to Shantha for the production of cholera vaccine. IVI also established and transferred tests to ensure the vaccine was of the highest quality and enabled improvements in production to keep manufacturing costs as low as possible.

"This important milestone validates Vabiotech's efforts and technical capability in developing and promoting the manufacture of an affordable cholera vaccine for the world's poorest people," said Dr. Nguyen Thu Van, Director General of Vabiotech. "We are eager to see this vaccine rapidly deployed, especially in endemic areas, amid recent outbreaks of cholera in Africa, Asia and the Caribbean."

A Phase III clinical trial performed by IVI and colleagues at India's National Institute of Cholera and Enteric Diseases was launched at a field site in Kolkata to evaluate the vaccine in people from ages one year and up. The results showed the vaccine to be safe and protective against cholera for three years in all age groups. Licensed in India in 2009, Shanchol was the first vaccine to be developed and licensed from the pipeline of vaccines being developed with support from the Bill & Melinda Gates Foundation

"Prequalification of the Shanchol vaccine by WHO represents a validation of Shantha's quality processes and the safety and efficacy of the vaccine," said Dr. Harish Iyer, Chief Executive Officer of Shantha Biotechnics. "This approval also reinforces our commitment to work with partners to provide vaccines against infectious diseases affecting developing countries."

The prequalification by WHO sets the stage for IVI's next planned phase of the vaccine, which is introducing Shanchol in countries where cholera remains a major public health problem, such as countries in Africa and South Asia where the disease is endemic. Recently IVI estimated that nearly 3 million cases requiring treatment and about 94,000 deaths are due to cholera in endemic countries. The large outbreak that erupted in Haiti in October 2010 demonstrates that the incidence and severity of the disease can shift dramatically over a short period of time. The Haitian health ministry reported that this outbreak had caused 194,095 cumulative cases and 3,819 deaths by January 16, 2011.

Also, West and Central Africa have recently been besieged by a major outbreak across the region. According to UNICEF, 85,000 cholera cases and 2,466 deaths have been reported this year so far, potentially making it one of the worst outbreaks in the region's history. Deploying Shanchol, in conjunction with other preventive interventions and treatment, could play a key role in saving lives both in countries where the disease is endemic and in settings of natural disasters or humanitarian crises.

"In light of the devastating cholera outbreaks in Haiti, Pakistan, Nepal and in several countries of Africa, there is a clear need for a solution to halt the countless deaths and suffering," said Dr. Loucq. "A vaccine like Shanchol should positively impact public health efforts to control cholera in these countries. Now that Shanchol is WHO prequalified, IVI is looking forward to working with governments and other organizations to introduce this vaccine and to make it widely available for use around the world."

"This demonstrates the power of vaccines to prevent epidemic diseases in people at risk," said Dr. Regina Rabinovich, Director of Infectious Diseases at the Bill & Melinda Gates Foundation. "We must continue to work together to ensure that everyone has access to affordable vaccines, no matter where they live."


'/>"/>
Contact: Tae Kyung Byun
tkbyun@ivi.int
82-119-773-6071
International Vaccine Institute
Source:Eurekalert

Related medicine news :

1. AMRI announces collaboration agreement with Lilly for in-sourced chemistry services
2. University of Michigan announces Eric J. Topol Professorship in Cardiovascular Medicine
3. Peter Thiel announces Breakout Labs to energize innovation
4. ESC announces review of Atrial Fibrillation Guidelines
5. The Waxman Foundation announces $25,000 grant in B-cell lymphoma research
6. INFORMS journal announces special issue on using logistics, analytics in humanitarian relief
7. ASTRO announces 2011 Fellows class
8. The New York Stem Cell Foundation announces new initiative for Parkinsons disease
9. AFAR announces the 2011 Hartford Scholars in Geriatric Medicine
10. AGA announces prestigious recognition award recipients
11. Sanofi Pasteur announces FDA approval of menactra meningococcal conjugate vaccine indication for infants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... ... July 26, 2017 , ... ... will host its 2017 Process Validation and Process Validation Statistics Conferences in ... to process validation lifecycle challenges faced by process validation professionals and statisticians ...
(Date:7/26/2017)... ... July 26, 2017 , ... “We are thrilled to be partnering with ... to schedule an appointment online in real time,” said Keith English, LocalMed CEO. “Allowing ... directory will bring more Six Month Smiles patients to their providers.” , Each month, ...
(Date:7/26/2017)... ... July 26, 2017 , ... The Amnesty Rally 2017 will ... Johnson Park at 3313 Bernstein Park Drive in Monroe (adjacent to the Louisiana Purchase ... to help reduce gun violence throughout Monroe. Citizens can turn in unregistered, illegally-held and ...
(Date:7/25/2017)... ... , ... “Now Hiring!” is a popular phrase at Home Delivery Incontinent ... sales for over 30 consecutive years and now plans to hire more than 100 ... excitement and growth at HDIS, following the company’s acquisition by Fortune 1000 company Domtar. ...
(Date:7/25/2017)... ... July 25, 2017 , ... ... finance management services to communities across North Carolina, is launching a charity event ... raise community support for the ongoing fight against bladder cancer. , The Bladder ...
Breaking Medicine News(10 mins):
(Date:7/21/2017)... and RESEARCH TRIANGLE PARK, N.C. ... (NASDAQ: UTHR ) announced today that it ... the market opens on Thursday, July 27, 2017. ... a teleconference on Thursday, July 27, 2017, at 9:00 ... 1-877-351-5881, with international callers dialing 1-970-315-0533.  A rebroadcast of ...
(Date:7/20/2017)... ST. PAUL, Minn. , July 20, 2017  Prime ... Officer, Jonathan Gavras , M.D., following today,s Institute for ... its report on the effectiveness and value of ... benefit manager on the policy roundtable at the meeting. ... there is not a material cost benefit to the use ...
(Date:7/15/2017)... -- Enterin Inc., a Philadelphia -based biotechnology ... announced the completion of a $12.7 million Series A financing ... well as the participation of existing investors. ... support of New Ventures III and our current investors, and ... potential of our platform technology to transform the course of ...
Breaking Medicine Technology: